HSCT provides effective treatment for lymphoproliferative disorders in children with primary immunodeficiency.
Prunotto G, Offor UT, Samarasinghe S, Wynn R, Vora A, Carpenter B, Gowdy C, McHugh K, Windebank KP, Rovelli AM, Slatter MA, Gennery AR, Veys P, Bacon CM, Bomken S, Lucchini G.
Prunotto G, et al. Among authors: gowdy c.
J Allergy Clin Immunol. 2020 Aug;146(2):447-450. doi: 10.1016/j.jaci.2020.03.043. Epub 2020 May 1.
J Allergy Clin Immunol. 2020.
PMID: 32371070
No abstract available.